Aurinia Pharmaceuticals’ (AUPH) “Outperform” Rating Reaffirmed at FBR & Co
FBR & Co reaffirmed their outperform rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a research note issued to investors on Tuesday. FBR & Co currently has a $9.00 price target on the stock.
AUPH has been the topic of a number of other reports. Leerink Swann reiterated an outperform rating and set a $7.00 price target on shares of Aurinia Pharmaceuticals in a research note on Monday. HC Wainwright upped their target price on shares of Aurinia Pharmaceuticals from $7.00 to $10.00 and gave the stock a buy rating in a research note on Wednesday, August 17th. Finally, Canaccord Genuity set a $10.00 target price on shares of Aurinia Pharmaceuticals and gave the stock a buy rating in a research note on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average target price of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 6.2943% during mid-day trading on Tuesday, reaching $3.7203. 4,765,248 shares of the company were exchanged. The firm’s market capitalization is $131.27 million. The stock has a 50-day moving average of $2.25 and a 200 day moving average of $2.74. Aurinia Pharmaceuticals has a 1-year low of $1.42 and a 1-year high of $4.49.
An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp boosted its stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned approximately 0.29% of Aurinia Pharmaceuticals worth $283,000 as of its most recent SEC filing. Institutional investors and hedge funds own 20.04% of the company’s stock.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.